MedPath

Efficacy and safety assessment of Centella asiatica as an herbal dietary supplement to reduce blood sugar levels in type II diabetes patients in Thailand.

Phase 1
Conditions
Type II diabetes
Registration Number
TCTR20230928003
Lead Sponsor
The Royal College of Physicians of Thailand
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
40
Inclusion Criteria

1. Type II Diabetes patient
2. Age 18-65 years old

Exclusion Criteria

1. Pregnancy or lactation
2. Type I diabetes
3. HbA1c level >= 10
4. On insulin treatment
5. Hypothyroidism or hyperthyroidism
6. Severe liver dysfunction within 6 months : alanin aminotransferase (ALT) or aspartate amionotransferase (AST) > 5 times of normal limit, INR > 6.5, Bilirubin > 17.5 mg/dL
7. Creatinine > 3.5 mg/dL or eGFR < 30 ml/min/1.73 m2 within 6 months
8. Severe allergy to Centella asiatica

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath